Sign In
Buy GRCL
$10.25
+0 (+0%)
At Close: May 20, 2024
Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT
08:00am, Friday, 21'st May 2021
SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discov
SUZHOU, China and PALO ALTO, Calif. , May 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing
Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer
04:01pm, Monday, 10'th May 2021
SUZHOU and SHANGHAI, China, May 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly eff
Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May
05:32pm, Friday, 30'th Apr 2021
SUZHOU and SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering a
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020
06:00pm, Friday, 23'rd Apr 2021
SUZHOU and SHANGHAI, China, April 23, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing hi
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines
07:01pm, Sunday, 18'th Apr 2021
Sinopharm, China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50% owned by Sinopharm. Shanghai's S
SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly ef
Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.
08:45am, Wednesday, 31'st Mar 2021
SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering a
Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day
08:00am, Wednesday, 17'th Mar 2021
SUZHOU and SHANGHAI, China, March 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering a
Gracell Biotechnologies, Inc. (GRCL) CEO Dr. William Cao on Q4 2020 Results - Earnings Call Transcript
02:09pm, Wednesday, 10'th Mar 2021
Gracell Biotechnologies, Inc. (GRCL) CEO Dr. William Cao on Q4 2020 Results - Earnings Call Transcript
Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate Update
04:01pm, Tuesday, 09'th Mar 2021
Reported interim readouts for lead CAR-T product candidates: FasTCAR-enabled dual-targeting BCMA/CD19 autologous CAR-T product candidate GC012F for the treatment of multiple myeloma and TruUCAR-enable
U.S. IPO Week Ahead: Canadian IT And German Chemicals Lead A Diverse 9-IPO Week
10:42am, Saturday, 30'th Jan 2021
U.S. IPO Week Ahead: Canadian IT And German Chemicals Lead A Diverse 9-IPO Week
Week In Review: Suzhou's Adagene To Stage $125 Million IPO On NASDAQ
04:39pm, Sunday, 24'th Jan 2021
Week In Review: Suzhou's Adagene To Stage $125 Million IPO On NASDAQ
SUZHOU and SHANGHAI, China, Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effi
China's Gracell Biotechnologies Lists on Nasdaq
08:23pm, Sunday, 10'th Jan 2021
Jan.10 -- William Cao, founder and chief executive officer of Gracell Biotechnologies, discusses the Shanghai-based company's initial public offering in the U.S. and its growth strategy. Gracell is de
